Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'Boring' Bodes Well For Future Of Intercept's Ocaliva

This article was originally published in Scrip

Executive Summary

There was nothing to be shocked about in the FDA's briefing documents released ahead of its April 7 meeting of its Gastrointestinal Drugs Advisory Committee (GDAC) for Intercept Pharmaceuticals Inc.'s obeticholic acid (OCA), a new molecular entity the company is seeking to market as Ocaliva to treat primary biliary cirrhosis (PBC), a rare and potentially fatal liver disease.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts